- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05031533
Dose-painting Radiation for LA-NSCLC (DPRLC)
A Prospective Study on the Efficacy, Safety and Immune Effects of Dose-painting Radiation for Locally Advanced Non-small Cell Lung Cancer(LA-NSCLC)
Study Overview
Status
Intervention / Treatment
Detailed Description
The study evaluated the effectiveness, safety and immune effects of dose-painting radiation in patients with locally advanced non-small cell lung cancer.
The primary endpoint is PFS. Secondary points contains ORR, OS, HRQoL, and safety.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tao Li
Study Contact Backup
- Name: Jiahua Lyu, Doctor
- Phone Number: +86-17713539529
- Email: winlttljh@163.com
Study Locations
-
-
-
Kunming, China
- Recruiting
- Yunnan cancer hospital
-
Contact:
- Yaoxiong Xia
-
Wanzhou, China
- Recruiting
- Chongqing University Three Gorges Hospital
-
Contact:
- Shichuan Chang
-
Yingchuan, China
- Recruiting
- General Hospital of Ningxia Medical University
-
Contact:
- Ren Zhao
-
Sub-Investigator:
- Yanyang Wang
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- Sichuan Cancer Hospital & Institute
-
Contact:
- Tao Li, Doctor
- Phone Number: 86-18908178818
- Email: litaoxmf@163.com
-
Sub-Investigator:
- Jiahua Lyu, doctor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient or the legal representative of the patient can sign a written informed consent, and can understand and agree to follow the research requirements;
- The age at the time of signing the informed consent form is between 18 and 75 years old;
- It is diagnosed as non-small cell lung cancer by histology, and is suitable for radical radiotherapy:
- Stage II-Ⅲ (AJCC 8th edition [Rice et al., 2017]) inoperable NSCLC patients (not medically suitable for surgery or refuse surgical intervention);
- Measurable lesions that meet the definition of RECISTv1.1;
- ECOG physical status ≤ 2;
- Survival expectancy ≥ 3 months;
- Hemoglobin ≥100g/L, WBC≥4×109/L, platelet ≥100×109/L (or follow the standards of each center);
- Liver function: ALT, AST<1.5 times the upper limit of normal (ULN), total bilirubin<1.5×ULN;
- Renal function: serum creatinine <1.5×ULN;
- Pulmonary function: FEV1>50%, the percentage of DLCO (lung diffusion function) measured value and predicted value>80% mild to moderate lung function impairment.
- The patient has good compliance with the treatment and follow-up.
Exclusion Criteria:
- There is evidence of distant metastasis (M1, AJCC 8th edition [Rice et al., 2017]);
- There is pleural effusion, pericardial effusion or ascites that is not clinically controlled and requires repeated drainage or medical intervention (within 2 weeks before randomization);
- Intolerance or resistance to the chemotherapy, targeted, and immunotherapy specified in the experimental protocol;
- Have received radiotherapy and surgical treatment;
- There were other active malignant tumors ≤ 2 years before enrollment, except for the specific cancers under study in this study and locally recurring cancers that have been cured (eg, resected basal cell or squamous cell skin cancer, superficial Bladder cancer, carcinoma in situ of the cervix or breast);
- A history of interstitial lung disease, non-infectious pneumonia or uncontrolled systemic diseases, including pulmonary fibrosis, acute lung diseases, etc.;
- Has suffered from other malignant tumors;
- Subjects who have received other drug trials within the past month;
- Pregnant or lactating women and women who refuse contraception during the treatment observation period;
- People with a history of severe allergies or idiosyncratic physique;
- Those with a history of severe lung or heart disease;
- Refusal or inability to sign the informed consent to participate in the trial;
- Drug or alcohol addicts;
- Personality or mental illness, lack of capacity for civil conduct or limited capacity for civil conduct.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Assigned Interventions
Radiation therapy: Dose-painting radiation Systemic treatment: Choose a systemic treatment plan according to the patient's genetic testing status (1) Chemotherapy
(2) Targeted therapy: According to the patient's genetic testing status, molecular targeted therapy such as EGFR-TKI and ALK inhibitors can be selected; (3) Immunotherapy: According to the patient's genetic testing status, immunotherapy such as PD1/PD-L1 inhibitors can be selected; |
Radiation therapy:
1) GTV-Tcentral: 2.0~2.5Gy/f, bid, 10-13d, physical dose 40-65Gy 2) GTV-Tperipheral: 3.0~4.0Gy/f, bid, 10-13d, physical dose 60-104Gy 3) GTV-N (mediastinal lymph node): 2.0Gy/f, bid, 10-13d, physical dose 40-52Gy |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
FPS
Time Frame: up to 3 years
|
progression-free survival (PFS) refers to the time from enrollment to the first recording of disease progression as determined by RECISTv1.1,
or to death due to any cause (whichever occurs first).
PFS will be analyzed in the ITT analysis set.
|
up to 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HRQoL
Time Frame: up to 3 years
|
HRQoL uses EORTCQLQ-C30 to assess the overall health of patients.
The post-baseline score of the treatment group was studied, and the score changes from the baseline were summarized descriptively.
|
up to 3 years
|
ORR
Time Frame: up to 3 years
|
Objective response rate, according to RECISTv1.1, the proportion of patients with CR or PR was determined.
If the patient has not undergone a post-baseline assessment, it is considered unremission
|
up to 3 years
|
OS
Time Frame: up to 3 years
|
OS(Overall survival) refers to the time from enrollment to the first recorded death due to any cause (whichever occurs first).
|
up to 3 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prognostic Biomarkers
Time Frame: up to 8 weeks
|
The expression of lymphocyte subsets in peripheral blood, including CD3+ T cells, CD4+ T cells, CD8+ T cells, CD8+CD28+ T cells, CD8+CD28- T cells, Treg cells, NK cells, NKT cells, γδ T cells;
|
up to 8 weeks
|
Prognostic Biomarkers
Time Frame: up to 8 weeks
|
The changing trend of various cytokines in radiotherapy, including IL-6, IL-1b, IL-9, TNF-a, TGF-β, IL-10, IL-21, etc.
|
up to 8 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCCHEC202108
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer Stage III
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)UnknownStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage III Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedStage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Mesothelin PositiveUnited States
-
National Cancer Institute (NCI)NRG OncologyTerminatedStage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
-
Assistance Publique - Hôpitaux de ParisBristol-Myers SquibbTerminatedNon Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage III | Non-Small Cell Carcinoma of LungFrance
Clinical Trials on Dose-Painting Radiation
-
Arcispedale Santa Maria Nuova-IRCCSCompletedGlioblastoma | Glioblastoma Multiforme | Glioblastoma, AdultItaly
-
Oslo University HospitalHaukeland University Hospital; St. Olavs Hospital; Norwegian University of Life...Not yet recruitingHead and Neck Cancer | Radiotherapy Side Effect
-
Oslo University HospitalNorwegian Cancer SocietyActive, not recruiting
-
Oslo University HospitalActive, not recruitingHead and Neck CancerNorway
-
Oslo University HospitalActive, not recruiting
-
University Hospital, GhentCompletedPrimary Non-operated Squamous Cell Carcinoma of Oral Cavity | Primary Non-operated Squamous Cell Carcinoma of Oropharynx | Primary Non-operated Squamous Cell Carcinoma of Hypopharynx | Primary Non-operated Squamous Cell Carcinoma of LarynxBelgium
-
Centre Francois BaclesseRecruiting
-
Jewish General HospitalCompletedCognitive ImpairmentCanada
-
University of ChicagoRecruitingLymphoma | Hodgkin Lymphoma | Non-hodgkin LymphomaUnited States
-
Istanbul Sabahattin Zaim UniversityCompletedMental Health IssueTurkey